Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the stock.

Oragenics Price Performance

Shares of NYSE OGEN opened at $0.30 on Wednesday. Oragenics has a 1 year low of $0.25 and a 1 year high of $6.22. The company’s 50-day moving average is $0.34 and its 200 day moving average is $0.63. The stock has a market capitalization of $3.62 million, a P/E ratio of -0.04 and a beta of 0.40.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.